Anthracycline-based chemotherapy in early breast cancer: Correlation with receptor status (estrogen, progesterone and human epidermal growth factor-2 /
Ahmed Abdelhamed Elsayed Oda
Anthracycline-based chemotherapy in early breast cancer: Correlation with receptor status (estrogen, progesterone and human epidermal growth factor-2 / العلاج الكيماوى بالانثراسيكلين فى سرطان الثدى المبكر و علاقته بحالة المستقبلات: الاستروجين و البروجستيرون و الهير 2 نيو Ahmed Abdelhamed Elsayed Oda ; Supervised Rabab Mohamed Gaafar , Ahmed Abdelmabood Zeeneldin , Amani Mohamed Helal - Cairo : Ahmed Abdelhamed Elsayed Oda , 2010 - 126 P. ; 25cm
Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology-Medical
Breast cancer (BC) is a heterogeneous disease that encompasses several distinct entities with different biological characteristics and clinical behavior. The purpose of this study is to correlate between the outcome of early breast cancer patients who received anthracycline-based chemotherapy with the tumor receptor status namely estrogen, progesterone and HER-2 receptor as regard disease free survival and overall survival
Anthracyclines Breast cancer Estrogen receptor
Anthracycline-based chemotherapy in early breast cancer: Correlation with receptor status (estrogen, progesterone and human epidermal growth factor-2 / العلاج الكيماوى بالانثراسيكلين فى سرطان الثدى المبكر و علاقته بحالة المستقبلات: الاستروجين و البروجستيرون و الهير 2 نيو Ahmed Abdelhamed Elsayed Oda ; Supervised Rabab Mohamed Gaafar , Ahmed Abdelmabood Zeeneldin , Amani Mohamed Helal - Cairo : Ahmed Abdelhamed Elsayed Oda , 2010 - 126 P. ; 25cm
Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology-Medical
Breast cancer (BC) is a heterogeneous disease that encompasses several distinct entities with different biological characteristics and clinical behavior. The purpose of this study is to correlate between the outcome of early breast cancer patients who received anthracycline-based chemotherapy with the tumor receptor status namely estrogen, progesterone and HER-2 receptor as regard disease free survival and overall survival
Anthracyclines Breast cancer Estrogen receptor